

Echo Australia 16-10-2010

Now I have the tools, how do I use in


Restrictive Cardiomyopathy

Lieng H. Ling, MBBS, MD, FRCP, FAMS
Yong Loo Lin School of Medicine
National University of Singapore

Conflicts: None

Introduction

- **Amyloid:** 'starch-like', first identified in humans by Virchow in 1854
- **Amyloids:** aggregations of undegraded protein fibrils because of misfolding mechanisms
- **Amyloidosis:** group of diseases characterized by insoluble extracellular deposition of amyloids



Classification Of Amyloidosis

Localized


- Alzheimers A-beta ($A\beta$)
- Diabetes Islet Amyloid Polypeptide (AIAPP)
- Calcitonin thyroid tumors (Acal)


Systemic

- Primary (AL): Ig light chains (k or λ)
- Secondary (AA): Serum amyloid A protein (SAA)
- Familial (ATTR): Mutated form of transthyretin
- Senile: Wild-type transthyretin, ANP, etc


Cardiac Amyloidoses

- Primary (AL)
- Familial Transthyretin (ATTR, variant)
- Senile (ATTR, wild-type)





Cardiac Amyloidosis




Worst prognosis with median survival <6 months and 5-year survival <10%


49/F, menopausal

- Presented 16-Jun-05
- LOW, LOA, N&V x 2 mo
- Dysuria, urgency, dizzy, backache
- PMH: Nil except Hep B carrier
- BP 120/80, HR 85
- No heart failure
- Liver 3 fb, firm

Lab Investigations

- Hb 13.6 /dL
- TW 8.3 x 10
- Plt 432 x 10
- FBG 4.5 mmol/L
- Urea 16.1 mmol/L
- Creat 585 μ mol/L
- UFEME - nad
- ESR 99
- Ca 2.16 mmol/L
- myeloma panel - λ chains
- Bone marrow - 4% plasma cells
- Skeletal survey - nad





What is the Diagnosis?


- A. LV hypertrophy
- B. Amyloid heart
- C. Hypertrophic cardiomyopathy
- D. Renal heart disease
- E. Need more tests



Conventional Echo


2D

- ↑ LV and RV thickness
- Normal or mildly reduced volumes
- Normal EF
- Biatrial enlargement
- Pericardial and/or pleural effusion
- Thickened valves/IAS



Doppler

- Diastolic dysfunction




Standard 2D-Doppler Echo Caveats

- Cannot confirm dx in isolation
- “Hypertrophy” has poor specificity
 - DDx: HHT, HCM, GSD, sarcoid, hemochromatosis, hyperoxaluria
 - ↑ LVM + ECG more sensitive (≤79%) and specific (≤100%)
- Sparkling myocardium
 - Not sensitive (≥26%), more specific (≤81%) ???

Case Control Study Design


- 103 patients with a proven diagnosis of primary systemic amyloidosis
- 32 age- sex-matched controls
- Classification:
 - LV thickness
 - E' velocity



CP1237840-17

Longitudinal DMI: Systole

□ Controls □ Non-ca □ Early ca □ Advanced ca




Bellavia et al. Am J Cardiol 2008;101:1039-1045

CP1237840-19

Longitudinal DMI: Diastole


□ Controls □ Non-CA □ Early CA □ Advanced CA



Bellavia et al. Am J Cardiol 2008;101:1039-1045

CP1238492-1

ROC: Non-CA vs Controls All DMI Techniques




Bellavia et al. Am J Cardiol 2008;101:1039-1045

CP1250380-4

Strain Imaging in Amyloid


- Longitudinal systolic strain is the most accurate modality for early diagnosis of CA
- Global average, or average of 6 basal segments are most accurate. Mean of 3 (or even 2) basal segments not significantly different



Are Filling Pressures Raised?

- A. No
- B. Yes, left-sided
- C. Yes, right-sided
- D. Yes, both






Will She Have a Good Outcome?

- A. Yes
- B. No
- C. Can't tell, need more data




Standard Echo *Evolution of Cardiac Fx*




Klein. *Circulation* 1991;83:808-81

Prognosis in Amyloid: Strain Imaging



Koyama, Falk. *J Am Coll Cardiol Img* 2010;3:333-42



LGE Common in Amyloid Heart
Patterns in Amyloid

A **B**

Circumferential subendocardial LGE (A) and diffuse LGE (B) in myocardium

Maceira. Circulation 2005;111:186-93
Perugini. Heart 2006;92:343-9

Late Gadolinium Enhancement

Transmural extension and number of enhanced segments correlated with LVEDV, LVESV, LA size
More diffuse LGE associated with poorer LV fx

Perugini. Heart 2006;92:343-9

Progress

23-Aug-05

- SOB, lethargy, leg edema
- Labs: Hb 8.5 g/dL, Na 113 mmol/L, Creatinine 882 $\mu\text{mol/L}$
- Hemodialysis commenced

30-Jun-06 s/p PBSCT

12-Jul-06 Demise

Conclusions

- Echo (and CMR) are useful tools for assessment of RCM
 - New modalities provide pathophysiologic info beyond standard echo
 - prognostication
 - monitor effects of Rx
